Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,861 to 2,880 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR) | 94 of 1,282 82 of 1,291 | 1.0 points -1.0 to 3.0 | 2,573 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI) | 67 of 1,282 53 of 1,291 | 1.1 points -0.5 to 2.8 | 2,573 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR) | 23 of 1,282 11 of 1,291 | 0.9 points 0.0 to 1.9 | 2,573 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF) | 77 of 1,282 64 of 1,291 | 1.0 points -0.7 to 2.8 | 2,573 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI | 74 of 1,282 64 of 1,291 | 0.8 points -0.9 to 2.6 | 2,573 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Part 1 (OLE): Etrolizumab vs Part 2 (PML SM): deaths from any cause | 9 of 1,773 1 of 796 | 0.4 points -0.2 to 0.8 | 2,569 | NCT02118584 Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies |
| Part 1 (OLE): Etrolizumab vs Part 2 (PML SM): serious adverse events | 373 of 1,773 2 of 796 | 20.8 points 18.8 to 22.8 | 2,569 | NCT02118584 Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies |
| Dabigatran 150 mg vs Warfarin: serious adverse events | 156 of 1,280 153 of 1,288 | 0.3 points -2.2 to 2.8 | 2,568 | NCT00680186 Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE) |
| Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography | 57 of 1,278 64 of 1,284 | -0.5 points -2.2 to 1.1 | 2,562 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Ferric Carboxymaltose (FCM) vs Iron Sucrose (Venofer): Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population. | 175 of 1,276 156 of 1,285 | 1.6 points -1.0 to 4.2 | 2,561 | NCT00981045 Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function |
| Ferric Carboxymaltose (FCM) vs Iron Sucrose (Venofer): serious adverse events | 202 of 1,276 197 of 1,285 | 0.5 points -2.3 to 3.3 | 2,561 | NCT00981045 Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function |
| Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR) | 110 of 1,264 97 of 1,279 | 1.1 points -1.0 to 3.3 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR) | 19 of 1,264 16 of 1,279 | 0.3 points -0.7 to 1.2 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR) | 33 of 1,264 15 of 1,279 | 1.4 points 0.4 to 2.6 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF) | 90 of 1,264 71 of 1,279 | 1.6 points -0.3 to 3.5 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI) | 75 of 1,264 62 of 1,279 | 1.1 points -0.7 to 2.9 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Rehospitalization | 227 of 1,265 237 of 1,278 | -0.6 points -3.6 to 2.4 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF) | 101 of 1,264 86 of 1,279 | 1.3 points -0.8 to 3.3 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR) | 32 of 1,264 15 of 1,279 | 1.4 points 0.3 to 2.5 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR | 19 of 1,264 16 of 1,279 | 0.3 points -0.7 to 1.2 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
Code
curl "https://conductscience.org/api/comparisons/v1?page=144"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=144
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02173379-ac93bf52",
"title": "Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR)",
"summary": "94 of 1282 against 82 of 1291; risk difference 1.0 points, 95% interval -1.0 to 3.0; NCT02173379, Absorb IV Randomized Controlled Trial",
"record": "/library/comparisons/NCT02173379-ac93bf52",
"nct_id": "NCT02173379",
"kind": "outcome",
"participants": 2573,
"risk_difference": {
"value": 0.009806279160539,
"lower": -0.009793787780965221,
"upper": 0.02950306763962557
},
"group_1": "94 of 1,282",
"group_2": "82 of 1,291",
"difference": "1.0 points",
"interval": "-1.0 to 3.0",
"trial_title": "Absorb IV Randomized Controlled Trial"
},
{
"id": "NCT02173379-af0992ab",
"title": "Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI)",
"summary": "67 of 1282 against 53 of 1291; risk difference 1.1 points, 95% interval -0.5 to 2.8; NCT02173379, Absorb IV Randomized Controlled Trial",
"record": "/library/comparisons/NCT02173379-af0992ab",
"nct_id": "NCT02173379",
"kind": "outcome",
"participants": 2573,
"risk_difference": {
"value": 0.011208643543263029,
"lower": -0.005191898163230152,
"upper": 0.02779572397084943
},
"group_1": "67 of 1,282",
"group_2": "53 of 1,291",
"difference": "1.1 points",
"interval": "-0.5 to 2.8",
"trial_title": "Absorb IV Randomized Controlled Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=145",
"request_id": "cUoeKDj-gq_3H5K7"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant